ARGONAUT

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....

Acute Myocarditis registry with Prognostic, Histologic, Immunologic, Biological, Imaging and clinical Assessment : The AMPHIBIA registry

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.